Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Accession Number
DB14444
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Influenza a Virus A/california/7/2009(h1n1)-like Antigen (Propiolactone Inactivated)

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Active Moieties
NameKindUNIICASInChI Key
Influenza A virus A/California/7/2009(H1N1)-like hemagglutinin antigen (propiolactone inactivated)hemagglutininK9P8PVA2UGNot AvailableNot applicable
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Influenza AInjection, suspension15 ug/0.5mLIntramuscularCsl Limited2009-07-012010-06-30Us
Influenza AInjection, suspension15 ug/0.5mLIntramuscularCsl Limited2009-07-012010-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
CX39D2R810
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDecreased Immunologic Activity [PE] / Flu caused by Influenza / Rejection1
4CompletedPreventionFlu caused by Influenza4
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Malignancies / Pediatrics / Rheumatic Diseases / Transplanted1
4WithdrawnTreatment2009 H1N1 Influenza1
3CompletedPreventionFlu caused by Influenza2
3CompletedPreventionFlu caused by Influenza / Influenza Vaccines1
3CompletedPreventionInfluenza Infection1
2CompletedBasic ScienceInfluenza A Virus, H5N1 Subtype1
2CompletedPreventionFlu caused by Influenza9

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular15 ug/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on July 05, 2018 12:03 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates